Characterization of bio-nanocapsule as a transfer vector targeting human hepatocyte carcinoma by disulfide linkage modification

Tadahiro Nagaoka, Takayuki Fukuda, Shinnosuke Yoshida, Hirohito Nishimura, Dongwei Yu, Shun'ichi Kuroda, Katsuyuki Tanizawa, Akihiko Kondo, Masakazu Ueda, Hidenori Yamada, Hiroko Tada, Masaharu Seno

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The bio-nanocapsules (BNCs) composed of the recombinant envelope L-protein of hepatitis B virus constitute efficient delivery vectors specifically targeting human hepatocytes. Here, we have tried to enhance the stability of the BNCs because the L-proteins in the BNCs were aggregated due to random disulfide bridging when stored for a long period at 4 °C. The envelope protein contains fourteen cysteine residues in the S domain. Aggregation of the envelope proteins might be avoided if unessential cysteine residues are replaced or removed because the irreversible alkylation of the free sulfhydryl group protects against the aggregation and enhances the efficiency of encapsulation. In this study, the possibility of reducing the number of cysteine residues in the S domain to enhance the stability of the BNCs was assessed. The replacement of each cysteine residue by site-directed mutation showed that nine of fourteen cysteine residues were not essential to obtaining BNCs secreted into the culture media. Furthermore, upon evaluating the combination of these mutations, it was found that eight residues of replacement were acceptable. The mutant BNCs with replaced eight cysteine residues were not only more resistant against trypsin, but also more effective in transducing genes into human hepatoma-derived HepG2 cells than the original type BNC. Thus, we demonstrated that the minimized number of cysteine residues in the S domain could enhance the stability of the BNCs.

Original languageEnglish
Pages (from-to)348-356
Number of pages9
JournalJournal of Controlled Release
Volume118
Issue number3
DOIs
Publication statusPublished - Apr 23 2007

Fingerprint

Nanocapsules
Disulfides
Hepatocytes
Cysteine
Carcinoma
Mutation
Proteins
Hep G2 Cells
Alkylation
Trypsin
Culture Media
Hepatocellular Carcinoma

Keywords

  • Bio-nanocapsule
  • Delivery vector
  • Enhanced stability
  • HBV surface antigen
  • Hepatocyte specific targeting

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Characterization of bio-nanocapsule as a transfer vector targeting human hepatocyte carcinoma by disulfide linkage modification. / Nagaoka, Tadahiro; Fukuda, Takayuki; Yoshida, Shinnosuke; Nishimura, Hirohito; Yu, Dongwei; Kuroda, Shun'ichi; Tanizawa, Katsuyuki; Kondo, Akihiko; Ueda, Masakazu; Yamada, Hidenori; Tada, Hiroko; Seno, Masaharu.

In: Journal of Controlled Release, Vol. 118, No. 3, 23.04.2007, p. 348-356.

Research output: Contribution to journalArticle

Nagaoka, T, Fukuda, T, Yoshida, S, Nishimura, H, Yu, D, Kuroda, S, Tanizawa, K, Kondo, A, Ueda, M, Yamada, H, Tada, H & Seno, M 2007, 'Characterization of bio-nanocapsule as a transfer vector targeting human hepatocyte carcinoma by disulfide linkage modification', Journal of Controlled Release, vol. 118, no. 3, pp. 348-356. https://doi.org/10.1016/j.jconrel.2006.12.020
Nagaoka, Tadahiro ; Fukuda, Takayuki ; Yoshida, Shinnosuke ; Nishimura, Hirohito ; Yu, Dongwei ; Kuroda, Shun'ichi ; Tanizawa, Katsuyuki ; Kondo, Akihiko ; Ueda, Masakazu ; Yamada, Hidenori ; Tada, Hiroko ; Seno, Masaharu. / Characterization of bio-nanocapsule as a transfer vector targeting human hepatocyte carcinoma by disulfide linkage modification. In: Journal of Controlled Release. 2007 ; Vol. 118, No. 3. pp. 348-356.
@article{1cf5769562604e1dabb348253582c915,
title = "Characterization of bio-nanocapsule as a transfer vector targeting human hepatocyte carcinoma by disulfide linkage modification",
abstract = "The bio-nanocapsules (BNCs) composed of the recombinant envelope L-protein of hepatitis B virus constitute efficient delivery vectors specifically targeting human hepatocytes. Here, we have tried to enhance the stability of the BNCs because the L-proteins in the BNCs were aggregated due to random disulfide bridging when stored for a long period at 4 °C. The envelope protein contains fourteen cysteine residues in the S domain. Aggregation of the envelope proteins might be avoided if unessential cysteine residues are replaced or removed because the irreversible alkylation of the free sulfhydryl group protects against the aggregation and enhances the efficiency of encapsulation. In this study, the possibility of reducing the number of cysteine residues in the S domain to enhance the stability of the BNCs was assessed. The replacement of each cysteine residue by site-directed mutation showed that nine of fourteen cysteine residues were not essential to obtaining BNCs secreted into the culture media. Furthermore, upon evaluating the combination of these mutations, it was found that eight residues of replacement were acceptable. The mutant BNCs with replaced eight cysteine residues were not only more resistant against trypsin, but also more effective in transducing genes into human hepatoma-derived HepG2 cells than the original type BNC. Thus, we demonstrated that the minimized number of cysteine residues in the S domain could enhance the stability of the BNCs.",
keywords = "Bio-nanocapsule, Delivery vector, Enhanced stability, HBV surface antigen, Hepatocyte specific targeting",
author = "Tadahiro Nagaoka and Takayuki Fukuda and Shinnosuke Yoshida and Hirohito Nishimura and Dongwei Yu and Shun'ichi Kuroda and Katsuyuki Tanizawa and Akihiko Kondo and Masakazu Ueda and Hidenori Yamada and Hiroko Tada and Masaharu Seno",
year = "2007",
month = "4",
day = "23",
doi = "10.1016/j.jconrel.2006.12.020",
language = "English",
volume = "118",
pages = "348--356",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Characterization of bio-nanocapsule as a transfer vector targeting human hepatocyte carcinoma by disulfide linkage modification

AU - Nagaoka, Tadahiro

AU - Fukuda, Takayuki

AU - Yoshida, Shinnosuke

AU - Nishimura, Hirohito

AU - Yu, Dongwei

AU - Kuroda, Shun'ichi

AU - Tanizawa, Katsuyuki

AU - Kondo, Akihiko

AU - Ueda, Masakazu

AU - Yamada, Hidenori

AU - Tada, Hiroko

AU - Seno, Masaharu

PY - 2007/4/23

Y1 - 2007/4/23

N2 - The bio-nanocapsules (BNCs) composed of the recombinant envelope L-protein of hepatitis B virus constitute efficient delivery vectors specifically targeting human hepatocytes. Here, we have tried to enhance the stability of the BNCs because the L-proteins in the BNCs were aggregated due to random disulfide bridging when stored for a long period at 4 °C. The envelope protein contains fourteen cysteine residues in the S domain. Aggregation of the envelope proteins might be avoided if unessential cysteine residues are replaced or removed because the irreversible alkylation of the free sulfhydryl group protects against the aggregation and enhances the efficiency of encapsulation. In this study, the possibility of reducing the number of cysteine residues in the S domain to enhance the stability of the BNCs was assessed. The replacement of each cysteine residue by site-directed mutation showed that nine of fourteen cysteine residues were not essential to obtaining BNCs secreted into the culture media. Furthermore, upon evaluating the combination of these mutations, it was found that eight residues of replacement were acceptable. The mutant BNCs with replaced eight cysteine residues were not only more resistant against trypsin, but also more effective in transducing genes into human hepatoma-derived HepG2 cells than the original type BNC. Thus, we demonstrated that the minimized number of cysteine residues in the S domain could enhance the stability of the BNCs.

AB - The bio-nanocapsules (BNCs) composed of the recombinant envelope L-protein of hepatitis B virus constitute efficient delivery vectors specifically targeting human hepatocytes. Here, we have tried to enhance the stability of the BNCs because the L-proteins in the BNCs were aggregated due to random disulfide bridging when stored for a long period at 4 °C. The envelope protein contains fourteen cysteine residues in the S domain. Aggregation of the envelope proteins might be avoided if unessential cysteine residues are replaced or removed because the irreversible alkylation of the free sulfhydryl group protects against the aggregation and enhances the efficiency of encapsulation. In this study, the possibility of reducing the number of cysteine residues in the S domain to enhance the stability of the BNCs was assessed. The replacement of each cysteine residue by site-directed mutation showed that nine of fourteen cysteine residues were not essential to obtaining BNCs secreted into the culture media. Furthermore, upon evaluating the combination of these mutations, it was found that eight residues of replacement were acceptable. The mutant BNCs with replaced eight cysteine residues were not only more resistant against trypsin, but also more effective in transducing genes into human hepatoma-derived HepG2 cells than the original type BNC. Thus, we demonstrated that the minimized number of cysteine residues in the S domain could enhance the stability of the BNCs.

KW - Bio-nanocapsule

KW - Delivery vector

KW - Enhanced stability

KW - HBV surface antigen

KW - Hepatocyte specific targeting

UR - http://www.scopus.com/inward/record.url?scp=33947303063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947303063&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2006.12.020

DO - 10.1016/j.jconrel.2006.12.020

M3 - Article

C2 - 17306405

AN - SCOPUS:33947303063

VL - 118

SP - 348

EP - 356

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 3

ER -